Clinical Trials Logo

Severe Allergic Asthma clinical trials

View clinical trials related to Severe Allergic Asthma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03480815 Completed - Clinical trials for Severe Allergic Asthma

Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab Therapy

Start date: January 20, 2017
Phase: N/A
Study type: Interventional

This is a randomized, controlled study with a 48-week treatment phase to determine the clinical efficacy of temperature controlled laminar flow device (TLA, Airsonettâ„¢) in the patients with severe allergic asthma who are withdrawal of omalizumab therapy

NCT ID: NCT01002976 Withdrawn - Clinical trials for Severe Allergic Asthma

Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma

OM-2009-XO
Start date: December 2009
Phase: Phase 4
Study type: Observational

Omalizumab is an anti-IgE recombinant humanized monoclonal antibody.The efficacy and tolerability of omalizumab have been demonstrated in patients with moderate-to-severe and allergic (IgE-mediated) asthma. Clinical benefit with omalizumab is observed when serum free IgE levels are reduced to 50 ng/mL or less. However, although the causal role of IgE in allergic disease is well established, the relationship between free IgE and clinical symptoms of asthma has not been accurately quantified. Recent study demonstrated that omalizumab and free IgE concentrations are correlated with clinical outcomes. In non responder to omalizumab the clinical symptoms show random fluctuations around baseline without any tendency toward improvement despite adequate suppression of free IgE. In these patients it may be the ratio of specific IgE to total IgE or inter-patient variability in the expression of FceRI on effector cells that define whether the patient will respond or not to omalizumab. This current study is designed to evaluate the mechanisms of responsiveness to omalizumab measuring the free IgE, specific IgE and the level of FceRI expression on the effector cell and the correlation to clinical response.